Last updated: July 19, 2026
Forest Laboratories Inc. v. Lupin Limited (1:13-cv-01604) Litigation Summary and IP Analysis
Forest Laboratories Inc. v. Lupin Limited (U.S. District Court, District of Delaware, case no. 1:13-cv-01604) is a patent infringement action tied to Lupin’s FDA Paragraph IV position for a Forest product. The docket and opinion text determine the asserted patents, claim construction posture, and whether the case resolved through trial, dismissal, summary judgment, or settlement. Without the underlying docket content (complaint, scheduling orders, asserted patent numbers, ANDA/Orange Book references, and the final judgment), a complete infringement-and-timeline analysis cannot be produced.
What patent estate was asserted in Forest v. Lupin 1:13-cv-01604?
Featured snippet: Cannot be stated from the case identifier alone. The asserted patents and claims are required to summarize the estate.
Which Orange Book patents were at issue?
Featured snippet: Not determinable without the complaint and/or the court’s substantive order listing the patents asserted under 35 U.S.C. § 271(e)(2).
Were method-of-use, formulation, or manufacturing patents asserted?
Featured snippet: Not determinable without the patent list and asserted claim categories in the complaint or claim chart.
What does the docket show about trial, summary judgment, or settlement in 1:13-cv-01604?
Featured snippet: Cannot be determined without docket events and the final disposition entry (e.g., judgment after bench trial, summary judgment, Rule 12 dismissal, or consent judgment).
Key litigation milestones to extract from the docket
Featured snippet: Not available in the prompt.
H3 Complaint filing date and venue-specific procedural posture
H3 Markman/claim construction hearing and order date
H3 Summary judgment or Daubert/other admissibility rulings
H3 Trial date set or stayed pending PTO/other parallel proceedings
H3 Settlement documentation (stipulation of dismissal, consent decree, or licensing agreement language in public filings)
How did claim construction affect Forest’s infringement theory in 1:13-cv-01604?
Featured snippet: Cannot be performed without the Markman order or summary-judgment reasoning.
Which claim terms were construed?
Featured snippet: Not determinable without the claim construction opinion or transcript.
Did the court address non-infringement vs invalidity defenses?
Featured snippet: Not determinable without the dispositive motion record.
When does exclusivity end, and what generic entry risk did Lupin face?
Featured snippet: A generic entry risk assessment requires the FDA product identity (ANDAs tied to the litigation), the Orange Book patent expiration and exclusivity windows, and the lawsuit disposition.
How to map lawsuit timing to exclusivity timelines
H3 Orange Book patent expiration vs 30-month stay vs settlement dates
H3 Likely “trigger dates” used in Hatch-Waxman disputes
H3 Whether the case resolved before or after a key regulatory milestone
What Paragraph IV positions did Lupin take, and how do they tie to the asserted patents?
Featured snippet: Cannot be stated without the ANDA/PIV narrative tied to the complaint.
Was the case about non-infringement, invalidity, or both?
Featured snippet: Not determinable without the infringement and invalidity counts.
How strong was Forest’s patent position in 1:13-cv-01604?
Featured snippet: Cannot be evaluated without claim scope, prosecution history context, and the court’s substantive rulings.
What invalidity theories were raised
H3 35 U.S.C. § 102/103 anticipation or obviousness
H3 35 U.S.C. § 112 indefiniteness or lack of written description/enablement
H3 Obviousness-type double patenting if applicable
Any enforceability or inequitable conduct issues
Featured snippet: Not determinable without the answer and motions.
What did the court ultimately decide in Forest v. Lupin (1:13-cv-01604)?
Featured snippet: Not determinable from the prompt.
Final outcome categories to identify from docket
H3 Judgment of infringement / non-infringement
H3 Judgment of invalidity (in whole or in part)
H3 Stipulation of dismissal (settlement or covenant not to sue)
H3 Dismissal for lack of standing, improper venue, or procedural defects
How does 1:13-cv-01604 compare with other Forest v. Lupin or Lupin ANDA cases?
Featured snippet: Not possible without comparing asserted products, patents, and results across other dockets.
Competitive landscape implications
H3 Whether Lupin’s launch was delayed or enabled
H3 Whether other ANDA filers entered in parallel
H3 Whether Forest enforced additional patents via continuations or follow-on patents
Key Takeaways
- A litigation summary that is specific enough for licensing, litigation planning, or generic launch risk requires the complaint-asserted patent list, docket events, and the final disposition.
- The case number alone (1:13-cv-01604) does not provide the facts needed to identify asserted patents, exclusivity timelines, dispositive rulings, or settlement terms.
- No actionable conclusions on claim construction impact, patent strength, or generic entry risk can be made from the information provided.
FAQs
- What product and ANDA were tied to Forest v. Lupin 1:13-cv-01604?
- Which specific patents did Forest assert in 1:13-cv-01604?
- Did the case end in summary judgment, trial, or settlement?
- How did the court treat claim construction in the asserted patents?
- What exclusivity and launch dates were affected by this litigation?
References
- Case: Forest Laboratories Inc. v. Lupin Limited, No. 1:13-cv-01604 (D. Del.).
